19. Slesarev, A. I. *Eur. J. Biochem.* **173,** 395–399 (1988).
20. Tse, Y.-C., Kirkegaard, K. & Wang, J. C. *J. biol. Chem.* **255,** 5560–5565 (1980).
21. Kovalsky, O. I., Kozyavkin, S. A. & Slesarev, A. I. *Nucleic Acids Res.* **18,** 2801–2805 (1990).

ACKNOWLEDGEMENTS. We thank G. Frey for *M. kandleri* cells, L. Liu for antibody against human topoisomerase I, H. Nash for λ Int protein, Y. C. Tse-Dinh for *E. coli* topoisomerase I, J. Wang for *S. cerevisiae* topoisomerase III and antibody against *E. coli* topoisomerase I, and C. Scheimer and K. Eichinger for technical assistance. The work was supported in part by funds from the Leibniz Preis (K.S.) and the NSF (J.A.L.), and by Alexander von Humboldt and Alfred P. Sloan fellowships (to A.I.S.).

CORRECTIONS

Mobile reactive centre of serpins and the control of thrombosis

R. W. Carrell, D. Ll. Evans & P. E. Stein

Nature **353,** 576–578 (1991)

OUR study demonstrated the mobility of the reactive centre loop of antithrombin by its induced insertion into the A-sheet of the same molecule to give the latent L-form. We have since observed that a related process simultaneously occurs owing to the insertion of the reactive centre loop of one molecule into the A-sheet of another. We have rechecked our original data and find that, although the resulting loop-sheet polymers share similar properties with the L-form, their presence invalidates the interpretation of the CD specta (Fig. 2 of the above letter). We have now shown that L-antithrombin is present in human plasma that has been pasteurized and we will publish separately the conditions under which it can be heat-induced from fresh plasma, in good yields free of polymers. Studies of this polymer-free L-antithrombin together with structural results by ourselves and others, confirm the conclusions in our paper as to the occurrence of the L-state, its properties and the accompanying changes in the heparin affinity of antithrombin. The new data support the overall results and conclusions of the study. □

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy

Yung-Kang Chow, Martin S. Hirsch, Debra P. Merrill, Lawrence J. Bechtel, Joseph J. Eron, Joan C. Kaplan & Richard T. D'Aquila

Nature **361,** 650-654 (1993)

SOME of the data reported in the above letter are incorrect. See Scientific Correspondence (this issue—**364,** 679; 1993) for details. □

Oncogene *ect2* is related to regulators of small GTP-binding proteins

Toru Miki, Cheryl L. Smith, Jason E. Long, Alessandra Eva & Timothy P. Fleming

Nature **362,** 462–465 (1993)

THE amino-acid numbering of Ect2 and CDC24 in Fig. 2*b* of this letter is incorrect. The numbers for Ect2 should be 279, 330, 382, 429 and 482 (from top to bottom). Amino acids of CDC24 are numbered according to the initial publication[18] and not according to the revised sequence as indicated in the figure legend. The amino-acid numbers for CDC24 according to the revised sequence[23] should be 280, 325, 376, 418 and 470. □

ERRATUM

Single-shell carbon nanotubes of 1-nm diameter

Sumio Iijima & Toshinari Ichihashi

Nature **363,** 603–605 (1993)

FIGURE 1*b* in this letter was reproduced with insufficient quality for some labelled features to be visible. The improved version on the right shows the features 4 and 5 (arrowed) that were indistinguishable previously. Also, in the sixth paragraph of the paper, "(arrow 4 in Fig. 2)" should have read "(arrow 4 in Fig. 1*b*)". □